Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA): Esophageal Neoplasms trials

The registry lists 14 Esophageal Neoplasms studies with Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) as lead sponsor. 3 are open to participants now and 0 have results posted.

Phase 1 4Phase 2 8No phase 5(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Timing of Comprehensive Local Treatment After First-Line Systemic Therapy in Oligometastatic Esophageal or Gastric AdenocarcinomaRecruitingNCT07000253Phase 2
• "Less-is-more in Barrett-surveillance" Care Evaluation of Barrett's Patients With Low-Risk in Whom Endoscopic Surveillance is Stopped. The BLISS Project.RecruitingNCT06803147
• Distribution of Lymph Node Metastases in Esophageal CarcinomaRecruitingNCT03222895
• Outcomes of Endoscopically Resected High-risk Mucosal and Low- and High-risk Submucosal Adenocarcinoma Arising in Barrett's EsophagusStatus unknownNCT04818476
• Blood-borne Assessment of Stromal Activation in Esophageal Adenocarcinoma to Guide Tocilizumab TherapyActive, not recruitingNCT04554771Phase 2
• Liposomal iRInotecan, Carboplatin or oXaliplatin for Esophagogastric CancerActive, not recruitingNCT03764553Phase 2
• Venous Thromboembolism and Bleeding Risk in Patients With Esophageal CancerCompletedNCT03646409
• PDL-1 Targeting in Resectable Oesophageal CancerCompletedNCT03087864Phase 2
• Regorafenib in Combination With Paclitaxel in Advanced Oesophagogastric CarcinomaCompletedNCT02406170Phase 1/2
• Feasibility Study of Adjuvant Treatment With S-1 and Oxaliplatin in Patients With Resectable Esophageal CancerCompletedNCT02347904Phase 1
• The Addition of Nab-paclitaxel (Abraxane) to First Line Treatment of Metastasized Oesophagogastric Carcinoma (ACTION)CompletedNCT02273713Phase 1/2
• Innovative MRI Techniques to Improve Treatment Stratification of Patients With Esophageal CancerCompletedNCT02253602Not applicable
• Feasibility Study of Chemoradiation, TRAstuzumab and Pertuzumab in Resectable HER2+ Esophageal CarcinomaCompletedNCT02120911Phase 1/2
• Chemoradiation and Panitumumab for Esophageal CancerCompletedNCT01077999Phase 2